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Tumor-reactive T cells become unresponsive in
advanced tumors. Here we have characterized a
common mechanism of T cell unresponsiveness in
cancer driven by the upregulation of the transcription
factor Forkhead box protein P1 (Foxp1), which pre-
vents CD8+ T cells from proliferating and upre-
gulating Granzyme-B and interferon-g in response
to tumor antigens. Accordingly, Foxp1-deficient lym-
phocytes induced rejection of incurable tumors and
promoted protection against tumor rechallenge.
Mechanistically, Foxp1 interacted with the transcrip-
tion factors Smad2 and Smad3 in preactivated CD8+
T cells in response to microenvironmental transform-
ing growth factor-b (TGF-b), and was essential for its
suppressive activity. Therefore, Smad2 and Smad3-
mediated c-Myc repression requires Foxp1 expres-
sion in T cells. Furthermore, Foxp1 directly mediated
TGF-b-induced c-Jun transcriptional repression,
which abrogated T cell activity. Our results unveil a
fundamental mechanism of T cell unresponsiveness
different from anergy or exhaustion, driven by TGF-
b signaling on tumor-associated lymphocytes under-
going Foxp1-dependent transcriptional regulation.
INTRODUCTION
Malignant progression promotes the selection of less immuno-
genic tumor variants (Vesely and Schreiber, 2013). However,
clinical evidence supports that T cells exert immune pressure
against the progression of even advanced cancers (Fridman
et al., 2011; Zhang et al., 2003). In addition, de novo elicitation
or reactivation of protective immunity is required for the effec-
tiveness of several conventional or targeted anticancer therapies
(Zitvogel et al., 2013). Still, established tumors are not spontane-
ously rejected by the immune system. Even when tumor cellsImremain immunogenic, the effector activity of tumor-reactive lym-
phocytes is weakened during malignant progression (Scarlett
et al., 2012). In tumor-bearing hosts, two key mechanisms medi-
ated by different transcriptional pathways (Crespo et al., 2013)
render tumor-reactive lymphocytes unresponsive through
defective T cell priming (anergy) (Zheng et al., 2012) or sustained
exposure to suboptimal antigen concentrations (exhaustion)
(Wherry, 2011).
Besides inherent T cell unresponsiveness, tumor, vascular,
stromal, and immune cells contribute to create an inflammatory
and metabolically hostile environment where multiple immu-
nosuppressive networks converge to abrogate residual T cell ac-
tivity (Zou, 2005). Expression of the inhibitory receptors PD-1,
LAG-3, and CTLA-4 (Baitsch et al., 2012) in leukocytes and tu-
mor cells also contributes tomaintain T cell inactivity. In addition,
Indoleamine 2,3-dioxygenase (IDO) and its tolerogenic meta-
bolites, immunosuppressive cytokines, or nitrogen-reactive spe-
cies all contribute to abrogate lingering lymphocyte activity in
most solid tumors. Interestingly, some immunosuppressive
pathways are more active in tumors infiltrated by activated
T cells (Spranger et al., 2013), suggesting that these patients
could be superior beneficiaries of immunotherapies targeting
immunosuppression. Indeed, emerging clinical evidence sup-
ports that blockade of tolerogenic pathways unleashes anti-
tumor immunity, but only in some patients (Pardoll and Drake,
2012). Understanding what is truly relevant for the abrogation
of protective immunity in different cancers is needed for imple-
menting more effective antitumor immunotherapies.
Transforming growth factor-b (TGF-b) is a lymphocyte inhibitor
secreted by multiple cells and frequently overexpressed in
aggressive cancers (Flavell et al., 2010; Wrzesinski et al.,
2007). Tumors induce dendritic cells (DCs) to secrete TGF-b,
promoting regulatory T cell (Treg) expansion and indirect sup-
pression of T cell effectors (Ghiringhelli et al., 2005; Hanks
et al., 2013). Conventional T cells also produce TGF-b. Interest-
ingly, in some models, T cell-derived TGF-b (including TGF-b
produced by Treg cells) is sufficient for antitumor T cell suppres-
sion, while ablation of TGF-b only in Treg cells has insignifi-
cant effects (Donkor et al., 2011). Furthermore, TGF-b can also
suppress effector cytokines in antitumor CD8+ lymphocytesmunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc. 427
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Foxp1 Drives Immunosuppression in Cancer(Ahmadzadeh and Rosenberg, 2005). However, the pathways
elicited by TGF-b signaling specifically in unresponsive tumor-
reactive T cells and their overall impact remain incompletely un-
derstood. TGF-b could inhibit T cell proliferation through Smad3
transcription factor-dependent repression of interleukin-2 (IL-2)
(McKarns et al., 2004) and also through IL-2-independent mech-
anisms that involve Smad3 binding to theMyc promoter (Freder-
ick et al., 2004). Still, it is unknown whether these pathways play
a major role in tumor-induced immunosuppression, or whether
other tumor-induced factors influence TGF-b-signaling.
Forkhead box (FOX) proteins are transcription factors with
pleiotropic functions in the development and activity of immune
cells. In naive T cells, constitutive expression of Foxp1 enforces
quiescence by repressing the IL-7 receptor, implying that a cell-
intrinsic, Foxp1-dependent transcriptional program actively
maintains naive lymphocytes ‘‘at rest’’ (Feng et al., 2011; Hamil-
ton and Jameson, 2012). Interestingly, Foxp1 is downregulated
in exhausted (but not in memory) CD8+ lymphocytes in chronic
viral infections (Doering et al., 2012), but the functional relevance
of this phenotype, or whether these patterns are recapitulated in
antitumor T cells, remain completely unknown.
Here, we report that Foxp1 is universally upregulated in human
and mouse tumor-infiltrating effector T cells. Foxp1 mediates
TGF-b signaling by interacting with Smad proteins as an obligate
transcriptional corepressor and is required for dampening anti-
tumor immunity. Our results identify a hitherto unknown mecha-
nism of tumor-induced effector T cell suppression involving
T cell-intrinsic transcriptional changes different from anergy or
exhaustion.
RESULTS
Tumor-Reactive T Cells Upregulate Foxp1 in the
Tumor Microenvironment
Foxp1 is downregulated in exhausted CD8+ T cells in chronic
viral infections (Doering et al., 2012). However, it has been shown
to enforce quiescence in naive lymphocytes (Feng et al., 2011),
and its role in antitumor T cells remains to be determined. To
define the expression of Foxp1 in human ovarian cancer-infil-
trating lymphocytes, we used antibodies that detect two Foxp1
isoforms in mouse T cells: constitutively expressed Foxp1a,
which maintains naive lymphocyte quiescence (Feng et al.,
2011), and inducible Foxp1d. Accordingly, we also identified
two predominant bands of 80 and 66 kDa in human T cells,
consistent with the size of Foxp1.1 (the >97% similar human or-
tholog of mouse Foxp1a) and the human counterpart of mouse
Foxp1d, respectively (Figure 1A). Compared to activated
(CD45RA) or naive (CD45RA+) T cells from the blood of different
healthy donors, CD8+ tumor-infiltrating lymphocytes (TILs) from
six randomly selected patients overexpressed both Foxp1 iso-
forms, in both primary and metastatic ovarian tumors (Figures
1A and 1B; see Figure S1A available online). Foxp1 upregulation
in ovarian cancer was independent of the exhaustion status of
T cells, because two different Foxp1 variants were expressed
at higher (although variable) amounts independently of PD-1
expression, the inhibitory receptor associated with exhaustion
in one third of ovarian cancer CD8+ TILs (Duraiswamy et al.,
2013). Foxp1 overexpression was not restricted to ovarian
TILs, because unexhausted (PD-1) CD8+ lymphocytes sorted428 Immunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc.from three different breast cancer specimens showed much
higher amounts of Foxp1 than CD45RA and CD45RA+ T cells
in peripheral blood from the same patients, although Foxp1
was only slightly upregulated in PD-1+ CD8+ T cells in these sam-
ples (Figures 1C and 1D). Importantly, Foxp1 overexpression
was not caused by mere homing to solid tissues, because
Foxp1 was higher in intratumoral lymphocytes than in T cells in
matching tumor-free tissue from multiple patients (Figure 1E;
Figure S1B). In addition, Foxp1 overexpressing CD8+ lympho-
cytes harvested from ovarian tissue exhibited lower FSC (asso-
ciated with smaller cell size), compared to their counterparts in
peripheral blood from the same patient (Figure 1F).
Because tumor-reactive T cells are contained in both PD-1
and PD-1+ fractions of TILs (Matsuzaki et al., 2010), we next
sought to define how tumor antigen-specific T cells upregulate
Foxp1 in the tumor microenvironment (TME). For that purpose,
we activated mouse splenic T cells with DCs pulsed with immu-
nogenic (UV- plus g-irradiated) ID8-Defb29-Vegf-a cancer cells,
a system that results in aggressive and widely disseminated or-
thotopic ovarian tumors (Cubillos-Ruiz et al., 2012; Cubillos-Ruiz
et al., 2009). As reported, 70% of de novo activated lympho-
cytes showed activation markers within 7 days (Nesbeth et al.,
2009; Nesbeth et al., 2010) (data not shown). Notably, recently
primed CD8+ T cells exhibited lower amounts of Foxp1a
compared to naive T cells (data not shown), while both Foxp1a
and Foxp1d (Feng et al., 2011) were upregulated in these cells
in vivo in the TME within 3 days after adoptive transfer (Fig-
ure 1G). Universal ovarian microenvironmental factors such as
hypoxia, PGE2, or Estradiol (Cubillos-Ruiz et al., 2010; Scarlett
et al., 2012) had no measurable effect on Foxp1 upregulation
in activated T cells (Figures S1C and S1D). Incubation with tu-
mor-derived regulatory DCs or myeloid-derived suppressor
cells (MDSCs) also had negligible effects on the expression of
any Foxp1 isoform (Figure S1D). In our hands, IL-6, IL-2, IL-23,
IL-17, IL-15, IL-7, or vascular endothelial growth factor-a (Vegf-
a) also did not affect Foxp1 amounts in activated T cells (Fig-
ure S1E). In contrast, signaling through the integrin ligand
ICAM-1, the chemokine CXCL12 and, to a lesser extent,
TGF-b, induced a modest but reproducible upregulation of
Foxp1, which was enhanced in an additive manner (Figure S1F).
Correspondingly, independently of their activation status or anti-
gen experience, CD45RA+ and CD45RA, CD69+ and CD69, or
CD44lo and CD44hi human breast TILs from different patients ex-
hibited comparable Foxp1 overexpression (Figure 1E; Figures
S1G and S1H). Therefore, TILs commonly upregulate Foxp1 in
response to cytokines, chemokines, and integrin ligands overex-
pressed in the TME. At least in some tumors Foxp1 overexpres-
sion occurs independently of exhaustion markers, and to a
greater amount than in quiescent (CD45RA+) peripheral T cells,
implicating a potential role of this transcription factor in impairing
antitumor immunity.
Foxp1 Overexpression Prevents Tumor-Reactive
T Cells from Proliferating in the TME and Eliciting
Tumor Rejection
To elucidate the biological consequences of Foxp1 overexpres-
sion in antitumor T cells, we primed naive Foxp1-deficient (from
Foxp1f/f Cd4 cre+ mice (Feng et al., 2011)) and wild-type T cells
(from Foxp1f/f littermates) with ID8-Defb29-Vegf-a-pulsed DCs.
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Figure 1. CD8+ T Cells Upregulate Foxp1 in the TME
(A) Foxp1 expression in PD-1 and PD-1+ CD8+ T cells flow-cytometry-sorted from six freshly dissociated stage III and IV human ovarian carcinoma specimens
(samples 4 and 5, primary tumors; samples 1, 2, 3, and 6, metastatic masses). CD45RA+ (resting or naive) and CD45RA (activated) CD8+ T cells from the
peripheral blood of two healthy donors were sorted and analyzed in parallel in two independent experiments.
(B) Normalization of Foxp1 protein expression in PD-1 and PD-1+ ovarian tumor-infiltrating CD8+ T cells with b-actin.
(C) Foxp1 expression in PD-1 and PD-1+ CD8+ T cells flow-cytometry-sorted from three freshly dissociated breast cancer specimens, as well as matching
peripheral blood from the same patients and a healthy donor.
(D) Densitometric normalization performed as in (B).
(E) Intracellular staining for Foxp1 in CD3+CD8+ gated CD45RA+ and CD45RA T cells from human breast tumors, tumor-free tissues and peripheral blood from
same patients.
(F) Comparative FSC analysis of CD8+ T cells contained in a freshly dissociated advanced ovarian carcinoma and matching peripheral blood.
(G) CD45.2+ naive T cell splenocytes were primed in vitro with bone-marrow-derived DCs (BMDCs) pulsed with double irradiated (UV+gamma) ID8-Defb29-Vegf-
a tumor cells for 7 days (day 7 effectors) and administered into the peritoneal cavity of congenic ID8-Defb29-Vegf-a tumor-bearing mice at day 23 after tumor
challenge. Three days later, transferred (CD45.2+) and endogenous (CD45.1+) CD8+ and CD4+ T cells were flow-cytometry-sorted from tumor ascites and
analyzed by immunoblot. Representative of two independent experiments. IB, immunoblotting.
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Foxp1 Drives Immunosuppression in CancerEx vivo stimulation resulted in comparable CD8+ and CD4+ ratios
in Foxp1+/+ and Foxp1/ lymphocytes (Figure 2A; Figure S2A).
When equal numbers of Foxp1-deficient and control tumor-
reactive T cells were adoptively transferred into congenic tu-Immor-bearing mice, the proportions and absolute numbers of
CD8+ T cells lacking Foxp1 were 4-fold increased (Figures 2A
and 2B). Accumulation of Foxp1/ CD8+ T cells in tumors was
the result of their in vivo expansion, as CellTrace Violet-labeledmunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc. 429
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Figure 2. Foxp1 Expression Regulates Antitumor Effector Functions and Proliferation of CD8+ T Cells in the TME
(A) Flow cytometric analysis of CD45.2+ Foxp1-deficient versus WT T cells identically primed against tumor antigens as in Figure 1G.
(B) Absolute cell number of these lymphocytes recovered from peritoneal wash 7 days after adoptive transfer into day 24 ID8-Defb29-Vegf-a tumor-bearing
congenic mice. Representative of four independent experiments (p < 0.05, Student’s t test).
(C) In vivo proliferation of tumor-reactive Foxp1-deficient versus WT CD8+ T cells. Lymphocytes primed for 7 days against tumor antigens were labeled with cell
trace violet, adoptively transferred into orthotopic advanced ovarian cancer-bearing congenic mice, and recovered from peritoneal wash 3 and 8 days later.
Representative of three experiments.
(D) Annexin V and 7AAD staining of tumor antigen-primed Foxp1-deficient and WT T cells recovered from tumor ascites at the indicated days after adoptive
transfer in three independent experiments.
(E) Proliferation of Foxp1/ and WT T cells either primed with BMDCs pulsed with irradiated and UV-treated NIH 3T3 cells followed by transfer into day 24 ID8-
Defb29-Vegf-a tumor-bearing congenic mice (left), or primed with tumor antigen and transferred into the peritoneal cavity of tumor-free congenic mice (right).
Representative of three experiments.
(F) ELISPOT analysis of identically primed T cells, sorted from tumor ascites 3 days after adoptive transfer into advanced ID8-Defb29-Vegf tumor-bearing
congenic mice, and restimulated with PMA and Ionomycin for 4 hr. Representative of three independent experiments (G) IFN-g and Granzyme B ELISPOT
analysis of T cells primed against tumor antigens as above for 7 days (p < 0.05, Student’s t test). Add data represent mean ± SEM.
Immunity
Foxp1 Drives Immunosuppression in Cancer
430 Immunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc.
15 20 25 30 35 40
0
1000
2000
3000
4000
T
um
or
 v
ol
um
e 
(m
m
3 )
Foxp1-/-
WT
B
Days
T
um
or
 v
ol
um
e 
(m
m
3 )
Days after tumor challenge
11 14 17 20 23 26 29
0
1000
2000
3000
4000
Foxp1-/-
T cells
WT T cells
PBS
C
*
Treatment
*
D
Foxp1-/- T cells WT T cells
Trp53-Kras tumors
0 10
0
20
40
60
80
100
40 60 80 100 120 140
Days
S
ur
vi
va
l (
%
)
Foxp1-/-
T cells
WT T cells
PBS
*
**
A
Treatment
Figure 3. Foxp1 Expression Impairs the Pro-
tective Function of Tumor-Reactive T Cells
(A) On day 24 after ID8-Defb29-Vegf-a tumor
challenge, 47 different CD45.1+ mice received 106
tumor antigen-primed (day 7) T cells from Foxp1-
deficient (n = 16) or WT (n = 15) CD45.2+ mice.
Sixteen additional control tumor-bearing mice
were treated with PBS. Data pooled from three
independent experiments. p < 0.0001, Mantel-Cox
test.
(B) Four tumor-bearing mice surviving >60 days
after treatment with Foxp1/ T cells and six con-
trol age-matched WT mice were rechallenged with
2 3 106 ID8-Defb29-Vegf-a tumor cells, adminis-
tered into the axillary flank. Tumor growth was
monitored in three independent experiments. p <
0.003, Student’s t test.
(C) Naive T cell splenocytes from Foxp1-deficient
or WT mice were primed for 7 days with BMDCs
pulsed with double (g- plus UV- irradiated) MPKAS
cells. Tumor-reactive T cells were delivered into
tumors formed from this cell line (2 3 106 cells) in
congenic mice (n = 9 receiving Foxp1/ and n = 9
receiving WT T cells), at days 8 and 14 after flank
tumor challenge. Eight additional flank tumor-bearing mice received PBS. Pooled from three independent experiments. p < 0.005 between tumor volume of
Foxp1-deficient T cells and either WT T cell or PBS treatment groups (Mann-Whitney) (mean ± SEM).
(D) Massive necrosis induced by intratumoral administration of Foxp1/, but not WT tumor-reactive T cells in C57BL/6 Trp53-Kras mice challenged with s.c.
adenovirus-Cre to induce flank sarcomas. Palpable tumors were injected 3–4 times with 106 tumor antigen-primed Foxp1-deficient versusWT T cells, at 5–6 day
intervals. Representative of three independent experiments. Scale bar represents 200 mM.
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Foxp1 Drives Immunosuppression in Cancertumor antigen-primed Foxp1-deficient, but not control CD8+
T cells selectively proliferated in the TME for at least 8 days (Fig-
ure 2C; Figure S2B). Foxp1 overexpressing T cells did not un-
dergo death, but remained unresponsive at tumor beds (Figures
2C and 2D; Figures S2B–S2E). Importantly, selective expansion
of Foxp1-deficient T cells was driven by response to cognate (tu-
mor) antigen, because Foxp1/ CD8+ T cells primed against
irrelevant antigen, or against tumor antigens but transferred
into tumor-free mice, did not proliferate (Figure 2E; Figure S2F).
Although the presence of Foxp1 abrogated the proliferative
capacity of tumor-reactive T cells in vivo, they retain their capac-
ity to produce IL-2 and >20% of them show CD69 expression
in vivo (Figures S2G and S2H). However, the expression of
Foxp1 abolished the effector activity of antitumor lymphocytes
after transfer into tumors (Figure 2F). Significantly higher
numbers of Foxp1-deficient T cells sorted from peritoneal
washes after 3 days in the TME reacted by secreting inter-
feron-g (IFN-g) and cytolytic Granzyme-B in recall ELISPOT
analysis, compared to identically handled control CD8+ lympho-
cytes (Figure 2F). Importantly, superior effector activity in the
absence of Foxp1 was amplified in the TME, compared to mild
differences found after in vitro priming (Figure 2G). Collectively,
these results indicate that the presence of Foxp1 in tumor-reac-
tive T cells is sufficient to prevent their effector activity in the TME
upon reencounter with cognate tumor antigens.
Accordingly, the adoptive transfer of tumor antigen-primed
T cells lacking Foxp1 dramatically delayed the progression of es-
tablished and aggressive ID8-Defb29-Vegf-a orthotopic tumors,
while identically activated WT T cells only induced modest pro-
tection (Figure 3A). Notably, a fraction of mice treated with
Foxp1-deficient T cells in every independent experiment did
not show signs of disease >4 months after tumor challenge. ToImdefine whether Foxp1-deficient lymphocytes promoted long-
term protection against tumor recurrences, we rechallenged
these mice with ID8-Defb29-Vegf-a flank (axillary) tumors. As
shown in Figure 3B, all long-term survivors rejected secondary
tumors, while all control (naive) mice developed >2 cm tumor
masses. As expected, mice with selective ablation of Foxp1 in
T cells also exhibited superior outcomes when they were directly
challenged with orthotopic tumors (Figure S3A).
To define whether the superior antitumor activity of Foxp1-
deficient T cells is applicable to non-ovarian malignancies, we
generated sarcoma cell lines (termed MPKAS) from tumors re-
sulting from the administration of adenovirus-Cre into the flank
of Trp53f/fLSL-KrasG12D/+ (Trp53-Kras) mice (Scarlett et al.,
2012). We pulsed DCs with immunogenic (g- plus UV-irradiated)
tumor cells and used them to de novo prime T cells. Again, the
growth of MPKAS flank tumors was significantly delayed when
Foxp1-deficient tumor-reactive T cells were administered
directly into the tumor mass, compared to identically stimulated
WT T cells (Figure 3C). In addition, intratumoral administration of
Foxp1-defective, but not control tumor-reactive T cells, induced
massive necrosis in flank tumors that were initiated with adeno-
virus-Cre in Trp53-Kras mice (Figure 3D; Figure S3B). Together,
these results confirm that the expression of Foxp1 is sufficient to
abrogate the protective activity of antitumor cytotoxic T cells in
the TME and identify an important mechanism of tumor-induced
T cell unresponsiveness.
Foxp1 Is Required for TGF-b-Induced Inhibition of CD8+
T Cells
To determine how cytotoxic T cells acquire the capacity to ex-
pand and elicit immune protection against malignant progres-
sion in the absence of Foxp1, we focused on the activity ofmunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc. 431
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Figure 4. Foxp1 Is Required for TGF-
b-Induced Suppression of CD8+ T Cells
(A) Proliferation analysis of cell trace violet-labeled
Foxp1-deficient and WT T cells, stimulated for
5 days with CD3 and CD28 beads, in the presence
or the absence of 5 ng/mL of TGF-b1. Cells were
stained for CD8, Annexin V and 7AAD. Represen-
tative of four independent experiments.
(B) T cells from the spleen and lymph nodes of
Foxp1f/f were transduced with Cre-recombinase
expressing MigR1-GFP retroviruses or the empty
vector. GFP+ (excised) CD8+ T cells were flow
cytometry-sorted after 48 hr, cell trace violet-
labeled, and CD3 and CD28-stimulated for 4–
5 days, in the presence or the absence of TGF-b1
(5 ng/mL). Representative of three independent
experiments.
(C) Growth kinetics of MPKAS sarcomas (n = 6 per
group) intratumorally treated at days 7 and 10 with
2 3 106 tumor antigen-primed (6 days) T cells that
were dnTGF-bRII (pre-incubated for 30 min with
5 mg/ml of anti-mouse CXCR4 or control IgG; both
from R&D), Foxp1/, or WT. Additional controls
received PBS (mean ± SEM).
Immunity
Foxp1 Drives Immunosuppression in CancerTGF-b, which is upregulated in the microenvironment of multiple
tumors. We observed that Foxp1-deficient CD8+ lymphocytes
were resistant to TGF-b-mediated inhibition in multiple indepen-
dent experiments, while WT T cell proliferation was abrogated in
the presence of TGF-b (Figure 4A). Correspondingly, Foxp1/
(and not Foxp1+/+) CD8+ T cells primed against tumor antigens
in the presence of TGF-b proliferated in vivo in the TME as effec-
tively as without TGF-b (Figure S4A). Resistance to TGF-b was
not the result of thymic selection or preactivation artifacts in
Foxp1-deficient CD8+ T cells, because retrovirus-Cre-induced
excision of Foxp1 in CD8+ T cells from (Cd4-cre) Foxp1f/f432 Immunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc.mice also allowed their expansion in the
presence of TGF-b, while mocked-trans-
duced lymphocytes remained inhibited,
despite the robust preactivation required
for retroviral transduction (Figure 4B; Fig-
ures S4B and S4C).
Next, we aimed to define whether resis-
tance to TGF-b was sufficient to explain
the superior antitumor protection elicited
by Foxp1-deficient CD8+ T cells. For that
purpose, we treated ID8-Defb29-Vegf-a
tumor-bearing mice with tumor antigen-
primed T cells carrying a dominant-nega-
tive TGF-bR type II (dnTGF-bRII), in which
TGF-b signaling is blocked (Chen et al.,
2005; Gorelik and Flavell, 2000). As
shown in Figure S4D, dnTGF-bRII T cells
elicited survival increases higher than
those induced by identically primed
T cells from WT littermates, despite the
fact that Foxp1 was still upregulated in
the TME (Figure S4E). Correspondingly,
MPKAS sarcoma-reactive dnTGF-bRII
T cells also elicited superior effectsagainst flank tumor growth, compared to WT lymphocytes (Fig-
ure 4C). Most importantly, combined blockade of CXCL12
signaling and TGF-b resistance prevented the upregulation of
Foxp1 in the TME (Figure S4F), resulting in antitumor effects
equivalent to the administration of Foxp1-deficient T cells (Fig-
ure 4C; Figure S4G). Therefore, although the blatant superiority
of Foxp1-deficient T cells is not fully recapitulated by TGF-
b-resistance alone, these results confirm that TGF-b is neverthe-
less a major contributor to antitumor T cell unresponsiveness.
Therefore, the capacity of Foxp1/ lymphocytes to overcome
TGF-b-mediated inhibition is relevant for their enhanced activity
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Figure 5. Foxp1 Deficiency Does Not Affect TGF-b-Induced Nuclear Translocation of Smad Signaling Molecules in CD8+ T Cells
(A) Immunoblot analysis of TGF-bRII expression in Foxp1-deficient and WT CD8+ T cells under various stimulation conditions.
(B) Expressions of Smad2 (upper band), Smad3 (lower band), and phosphorylated Smad2 (p-Smad2) in Foxp1-deficient and WT CD8+ T cells at rest or CD3 and
CD28-activated for 24 hr, in the presence or the absence of TGF-b1 (5 ng/mL).
(C) Expression of p-Smad3 (Ser423 and Ser425) in Foxp1-deficient and WT CD8+ T cells stimulated in vitro with CD3 and CD28-beads for 24 hr, followed by
TGF-b1 (5ng/ml) treatment for 30 min.
(D and E) Confocal microscopy analysis of resting and CD3 and CD28-stimulated (24 h) Foxp1-deficient andWT CD8+ T cells (±TGF-b1; 5 ng/ml). Representative
of three independent experiments. Scale bar represents 10 mM.
Immunity
Foxp1 Drives Immunosuppression in Cancerin the TME, and combined TGF-b and CXCL12 signals cause
Foxp1 overexpression in at least some tumors.
We then aimed to elucidate the mechanism whereby Foxp1-
deficient CD8+ T cells become resistant to TGF-b-mediated in-
hibition. In the canonical TGF-b pathway, binding of TGF-b to a
TGF-bRI and TGF-bRII receptor dimer drives phosphorylation
and nuclear translocation of Smad2 and Smad3 molecules,
which interact with corepressors to suppress T cell function
(Siegel and Massague´, 2003). We therefore first ruled out
repression of either the TGF-bR or downstream Smad2 and
Smad3 by Foxp1, at either resting or activated stages (FiguresIm5A and 5B). Furthermore, Smad2 and Smad3 phosphorylation
occurred as effectively in control T cells as in Foxp1-deficient
lymphocytes (Figures 5B and 5C). Smad4-dependent nuclear
translocation of Smad2 and Smad3 (Siegel and Massague´,
2003) was also unaffected by the absence of Foxp1, as
shown by immunofluorescent analysis of Foxp1-deficient
CD8+ T cells treated with TGF-b (Figure 5D). Collectively,
these data indicate that Foxp1 is required for TGF-b-mediated
inhibition of tumor-reactive T cells, through a mechanism that
takes place downstream of Smad2 and Smad3 translocation,
which is sufficient to explain why Foxp1/ lymphocytesmunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc. 433
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(A) HeLa cells were transiently transfected with
HA-tagged human Smad2 (Smad2-HA) and Flag-
tagged human Foxp1.1 (Foxp1-Flag), treated or
not with 5 ng/ml of TGF-b1 for 12 hr, crosslinked,
and lysed. HA was immunoprecipitated from the
extracted proteins, followed by immunoblotting for
Flag. HA IP from untransfected, Smad2-HA only
transfected HeLa cell lysates, and irrelevant
(a-Lck) IgG immunoprecipitated from Smad2-HA
and Foxp1-Flag transfected cell lysates were used
as IP controls. Representative of four independent
experiments.
(B) Reverse IP with Flag and immunoblotting for
Smad2 and Smad3 from transiently transfected
HeLa cells described above. Representative of two
independent experiments.
(C) Primary human CD8+ T cells were electro-
porated with Smad2-HA and Foxp1-Flag. After 6-
12 hr, cells were CD3 and CD28-stimulated for
24 hr (±5 ng/ml TGF-b1), crosslinked, and lysed. IP
was carried out with anti-HA antibody and irrele-
vant IgG followed by immunoblotting for Flag.
(D) Endogenous Smad2 and Smad3 was IPed from
the whole-cell lysates of WT and Foxp1-deficient
T cells CD3 and CD28-activated in the presence
of TGF-b1 (5 ng/ml). IP with irrelevant IgG was
simultaneously performed. IPed proteins were
immunoblotted and probed with anti-Foxp1 anti-
bodies. Representative of three independent ex-
periments. IP, immunoprecipitation.
Immunity
Foxp1 Drives Immunosuppression in Cancerremain responsive in the TME and exert superior antitumor
protection.
Foxp1 Is a Component of Smad Nuclear
Repression Complex
To define whether Foxp1 interacts with Smad2 and Smad3 pro-
teins in the nucleus after TGF-b-induced translocation, we next
performed confocal microscopy analysis of primary human and
mouse CD8+ T cells. As shown in Figure 5E, Foxp1 colocalized
with Smad2 and Smad3 in the nucleus of T cells after TGF-b
signaling. Because in some cell types, Smad2 and Smad3 part-
ner with other transcriptional repressors such as TGIF and
CtBP1 (Postigo et al., 2003; Siegel and Massague´, 2003), we hy-
pothesized that Foxp1 could be a necessary component of the
transcriptionally repressive Smad2 and Smad3 complex in
CD8+ T cells. To confirm the physical interaction between
Smad and Foxp1, we stably cotransfected HeLa cells with
Flag-tagged human Foxp1 and hemagglutinin (HA)-tagged hu-
man Smad2. Immunoblot analysis confirmed that immunopre-
cipitates of tagged Smad2 contained a band corresponding to
Flag-tagged Foxp1 that was recognized by a-Flag antibodies
(Figure 6A). Coimmunoprecipitation of Foxp1 and Smad2 was
specific because abundant proteins such as b-actin were not
pulled down, and immunoprecipitates of irrelevant (a-Lck) Abs
did not contain Foxp1 (Figure 6A). Correspondingly, reverse
(a-Flag Foxp1) immunoprecipitates, but not irrelevant pull-
downs, contained interacting Smad2 and Smad3 proteins in in-
dependent experiments (Figure 6B).434 Immunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc.To verify that Smad2 and Foxp1 also interact in primary human
T cells, we nucleofected CD3 and CD28 preactivated lympho-
cytes from the peripheral blood of two different healthy donors
with tagged Smad2 and Foxp1. Immunoprecipitation (IP) of
Smad2-HA, but not of (irrelevant) Lck, again specifically pulled
down Flag-tagged Foxp1 and not b-actin (Figure 6C), confirming
that Foxp1 physically binds to the Smad2 and Smad3 complex
also in primary T cells.
Finally, to confirm the interaction between endogenous
Smad2 and Foxp1 in primary lymphocytes, we CD3- and
CD28-activated mouse T cell splenocytes (both Foxp1-deficient
and control lymphocytes) in the presence of TGF-b and per-
formed new immunoprecipitation analysis. As expected, immu-
noprecipitates of a-Smad2 and Smad3 Abs (but not irrelevant
a-Lck Abs) contained endogenous Foxp1 and not b-actin, and
that occurred only when control Foxp1+ T cells were used (Fig-
ure 6D). These results demonstrate that Foxp1 physically inter-
acts with the transcriptional repressor complex orchestrated
by Smad2 and Smad3 in CD8+ T cells upon TGF-b-induced nu-
clear translocation.
Foxp1 Mediates Transcriptional Repression of c-Myc
and c-Jun in CD8+ T Cells in Response to TGF-b
Signaling
Because Foxp1-deficient CD8+ T cells are resistant to TGF-
b-mediated inhibition, and because Foxp1 and Smad2 and
Smad3 interact in the nucleus, our results imply that Foxp1 is a
required element for the repressive effects of TGF-b. To confirm
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Figure 7. Foxp1 Is Required for TGF-
b-Induced Repression of c-Myc and c-Jun
in CD8+ T Cells
(A) Foxp1/ and WT CD8+ T cells were CD3 and
CD28-stimulated (±TGF-b1, 5 ng/ml) for 24 hr. Pro-
teins were isolated and immunoblotted for c-Myc.
(B) Foxp1 binding to the Myc promoter. Chro-
matin was immunoprecipitated with anti-Foxp1 or
control IgG from negatively immunopurified
mouse CD8+ T cells activated for 24 hr (+TGF-b1;
5 ng/ml). Enrichment of the Myc promoter
sequence in chromatin immunoprecipitated with
anti-Foxp1 Abs versus irrelevant IgG (top) and
percent of input samples before immunoprecipi-
tation (2.5% gel input values; bottom) were
quantified by real-time qPCR. The mouse MISIIR
gene promoter (GenBank#AF092445) was used as
an additional negative control. Representative of
two independent experiments.
(C and D) Immunoblot analysis of Foxp1/ and
WT stimulated with CD3 and CD28 (±TGF-b1,
5 ng/ml) for 24 hr for Nfat 2 (C) or for Jun and
phospho-(serine 73)-c-Jun (D). Blots were strip-
ped and reprobed with b-actin as an endogenous
normalization control. Representative of three in-
dependent experiments.
(E) ChIP PCR of mouse CD8+ T cells activated for
24 hr (±TGF-b1; 5 ng/ml) for c-Jun promoter
sequence as described above. Representative of
two independent experiments.
(F) CD45.2+ WT mouse T cells were transduced
with murine c-Jun, and congenic CD45.1+ T cells
were infected with the empty pBMN-I-GFP retro-
viral vector. GFP+CD8+ cells were flow cytometry-
sorted based upon CD45.1 and CD45.2 after 48 hr
and CD3 and CD28-restimulated for 24 hr (±TGF-
b1; 5 ng/ml). Proteins isolated from cell lysates
were immunoblotted for total and Ser73 phos-
phorylated c-Jun. Representative of two inde-
pendent experiments.
(G) Positively c-Jun-transduced CD45.2+ T cells
and mocked-transduced CD45.1+ congenic T cells
were flow cytometry-sorted based on GPF ex-
pression, pooled at 1:1 ratio, rested for one day,
and labeled with cell trace violet. Proliferation in
response to CD3 and CD28-stimulation for 3–
5 days, in the presence or the absence of TGF-b1
(5 ng/mL), was quantified by flow cytometry. Gated
on CD8+ T cells. Annexin V and 7ADD staining were
performed to discard dead and apoptotic cells.
Representative of three independent experiments.
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Foxp1 Drives Immunosuppression in Cancerthis proposition, we focused on the cell-cycle promoter Myc, a
known target of the TGF-b pathway that is transcriptionally
repressed through direct binding of Smad to its promoter (Yagi
et al., 2002). As shown in Figure 7A, TGF-b greatly diminished
CD3 and CD28-induced c-Myc overexpression in Foxp1+
T cells, whereas it had negligible effects on identically treated
Foxp1-deficient CD8+ lymphocytes. As expected, ERK inhibitors
abrogated Myc upregulation independently of Foxp1 (Fig-
ure S5A). To determine whether Foxp1 physically associates
with theMyc promoter, we performed chromatin immunoprecip-
itation (ChIP) with specific Abs. As shown in Figure 7B, we
observed enrichment of the fragment of the Myc promoter
containing a reported Smad binding site (Yagi et al., 2002) inImFoxp1-DNA precipitates, compared to control pull-downs with
an irrelevant immunoglobulin G (IgG). Supporting the specificity
of the binding to theMyc promoter, no enrichment was found for
the sequence of a control (MISIIR) promoter, primarily expressed
in Mullerian epithelium (Figure 7B).
To identify additional Foxp1-dependent mechanisms that
explain the superior activity of Foxp1-deficient T cells in the
TME, we finally focused on concurrent activation of nuclear fac-
tor of activated T cells (NFAT) and AP-1, a coordinated process
needed for optimal T cell effector function (Macia´n et al., 2002).
We found that CD3 and CD28-induced NFAT2 upregulation was
not affected by TGF-b signaling or the absence of Foxp1 expres-
sion (Figure 7C). In contrast, the expression of total c-Jun, amunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc. 435
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Foxp1 Drives Immunosuppression in Cancercrucial component of the AP-1 transcriptional complex in T cells
(Chen et al., 1998; Li et al., 2012), was increased in TGF-
b-treated Foxp1/ T cells, compared to WT lymphocytes (Fig-
ure 7D). Most importantly, c-Jun phosphorylation in CD3 and
CD28-activated T cells was decreased upon TGF-b signaling,
in a Foxp1-dependent manner (Figure 7D). Therefore, Foxp1 is
required for TGF-b-induced reduction of the AP-1/NFAT ratio
in CD8+ T cells, which is associated with T cell unresponsiveness
(Macia´n et al., 2002). As demonstrated for c-Myc, we observed
enrichment of c-Jun promoter sequences in Foxp1-DNA precip-
itates, suggesting that the TGF-b-induced complex inhibits c-
Jun through transcriptional repression (Figure 7E). In addition,
enrichment was higher when T cells were activated in the pres-
ence of TGF-b (Figure 7E). Together, our results indicate that
the Foxp1-mediated inhibitory program triggered by TGF-b in-
cludes direct transcriptional suppression of at least two impor-
tant transcription factors required for optimal T cell activation;
namely, c-Myc and AP-1.
Restoring c-Jun Expression Overcomes Foxp1-
Dependent TGF-b-Mediated Inhibition in CD8+ T Cells
To determine the unknown consequences of transcriptional
repression of c-Jun in T cells, we retrovirally expressed c-Jun
in mouse (Foxp1+) WT T cells. Sustained CD3 and CD28-medi-
ated T cell activation, which is required for retroviral transduc-
tion, resulted in ablation of c-Jun expression in mock-trans-
duced CD8+ T cells. As expected, identically preactivated,
positively transduced lymphocytes, expressed high amounts of
c-Jun, and overexpression was unaffected by TGF-b signaling
(Figure 7F). Ectopic expression of total c-Jun also resulted in
high amounts of phosphorylated (activated) c-Jun, suggesting
that transcriptional repression induced by the Foxp1and Smad
complex is sufficient to impair AP-1-mediated T cell activation
(Figure 7F). Supporting this, c-Jun-transduced CD8+ T cells
overcame the inhibitory effects of TGF-b on CD3 and CD28-
induced expansion (Figure 7G). Of note, mock transduced
CD8+ lymphocytes also exhibited a reduction of their prolifera-
tive capacity upon TGF-b-mediated signaling, regardless of the
sustained CD3 and CD28 preactivation required for retroviral
transduction (Figure 7G). Taken together, these results unravel
an unknown mechanism of CD8+ T cell inhibition whereby
Foxp1 represses the transcription of c-Jun, which impairs
TCR-induced restimulation of CD8+ T cells in the presence of
TGF-b.
DISCUSSION
We have identified a mechanism of T cell unresponsiveness
driven by upregulation of Foxp1 in tumor-associated CD8+
T cells. Foxp1 enforces proliferation arrest upon encounter
with cognate tumor antigens in CD8+ lymphocytes in vivo. Addi-
tionally, Foxp1 impairs T cell effector functions by decreasing
cytolytic Granzyme-B and IFN-g in antitumor T cells. These ef-
fects are induced by multiple tumor microenvironmental factors
that upregulate Foxp1 in the nucleus of local lymphocytes, thus
licensing physical interactions with Smad2 and Smad3 translo-
cated in response to TGF-b signaling. Foxp1 is correspondingly
required for the suppressive activity of TGF-b on CD8+ T cells,
including transcriptional repression of c-Myc and c-Jun.436 Immunity 41, 427–439, September 18, 2014 ª2014 Elsevier Inc.Overall, Foxp1 was overexpressed in tumor-infiltrating CD8+
T cells, compared to their counterparts in nearby tumor-free
tissue, and regardless of antigenic experience. In the ovarian
cancer microenvironment, Foxp1 overexpression occurs at
similar concentrations in PD-1+ (recently activated or exhausted)
versus PD-1neg T cells, and also independently of recent activa-
tion (CD69 expression). In contrast, Foxp1 overexpression
occurred to a lesser extent in breast cancer-infiltrating PD-1+
versus PD-1 CD8+ T cells. This could reflect a different degree
of exhaustion in PD-1+ T cells in the breast versus the ovarian
tumor microenvironment and/or result from the potentially dis-
similar immunogenicity of these malignancies. Elucidating the
differences between exhaustion and Foxp1-driven transcrip-
tional programs in different tumors provides exciting targets for
future investigations.
We also found that tumor antigen-primed T cells upregulate
Foxp1 after homing to the TME, which is in contrast with
sustained Foxp1 downregulation exhibited by exhausted
CD8+ lymphocytes in chronic viral infections (Doering et al.,
2012). While multiple inhibitory mechanisms identified in
chronic infections also play a role in the suppression of anti-
tumor immunity, solid tumors orchestrate different microenvi-
ronments. Our results underscore the importance that these
differences, along with specific tolerogenic networks in the
TME (Cui et al., 2013; Watkins et al., 2011; Zou, 2005), and/or
the weaker nature of tumor antigen-specific responses (Wang
et al., 2006; Zhu et al., 2013), might have on tumor-induced
immunosuppression.
Our results also provide some mechanistic clues to under-
stand how TGF-b inhibits effector T cells in cancer and other
pathological settings. Although Foxp1 is clearly involved in addi-
tional mechanisms of T cell unresponsiveness, we have identi-
fied Foxp1 as a necessary transcriptional corepressor in the
Smad inhibitory complex. Notably, Foxp1 expression does not
promote T cell death in vivo. Instead, Foxp1 is required for
TGF-b-dependent inhibition of both proliferative and effector
(Granzyme-B and IFN-g production) responses. Inhibition of
T cell expansion involves direct transcriptional repression of
c-Myc in CD8+ T cells. In addition, different concentrations
of c-Jun are important for the intensity of T cell activation in
the presence of TGF-b. Foxp1, by directly binding to the c-Jun
promoter, represses c-Jun expression, but not NFAT, resulting
in decreased activated (phosphorylated) c-Jun and impairing
T cell activation in CD8+ lymphocytes.
Our study shows that Foxp1-deficient CD8+ T cells have supe-
rior antitumor effector functions. Although Foxp1-deficient T cell
immunotherapy prolonged survival and protected mice from
secondary tumor challenges, we failed to recover adoptively
transferred cells from tumor-free mice. Thus, Foxp1-deficient
T cells, besides directly targeting tumor cells, might boost host
endogenous antitumor immunity (Nesbeth et al., 2009). It’s
possible that Foxp1 has unique functions in naive and memory
T cells, such that differentiation and survival of memory T cells
might require Foxp1 expression. However, Foxp1 function in
memory T cell differentiation remains unknown.
We mainly focused on CD8+ T cells in this study for several
reasons. We observed enhanced persistence and activity of tu-
mor antigen-primed Foxp1-deficient CD8+ T cells, but not CD4+
T cells. Furthermore, proliferation of Foxp1-deficient orWTCD4+
Immunity
Foxp1 Drives Immunosuppression in CancerT cells was not affected by TGF-b. However, we acknowledge
the potential importance of Foxp1 in CD4+ T cells, especially in
generating host effector and memory populations, a focus of
our future studies.
The molecular pathways by which Foxp1 impairs the effector
activity of TILs demands further investigation, but Smad factors
are known to bind to the Granzyme-B and IFN-g promoters
(Thomas and Massague´, 2005). It is therefore likely that Foxp1
also mediates these suppressive effects. Correspondingly, we
found that adoptively transferred tumor-reactive Foxp1-deficient
T cells are able to induce the regression of aggressive estab-
lished tumors, without noticeable toxicity. Foxp1-dependent
repression therefore emerges as fundamental mechanism of
T cell unresponsiveness, different from other transcriptional pro-
grams such as anergy or exhaustion. Ablation of Foxp1 in tumor
antigen-primed or chimeric receptor antitumor T cells (e.g.,
through TALEN or CRISPR technologies) could empower lym-
phocytes to resist immunosuppressive networks in solid tumors,
thus allowing more effective clinical interventions.
EXPERIMENTAL PROCEDURES
Mice
Female C57BL/6 and congenic CD45.1+ Ly5.2 mice, aged 5–6 weeks were
purchased from the Frederick Cancer Research Facility of the National Cancer
Institute. Foxp1f/f and Foxp1f/f Cd4-Cremice (Feng et al., 2011) were provided
by Hui Hu and backcrossed with C57BL/6 mice for 12 generations. dnTGF-
bRII mice (Chen et al., 2005; Gorelik and Flavell, 2000) procured from the
Jackson Laboratories were used at 6 weeks of age. Trp53-Kras (p53/K-ras)
double-transgenic mice in C57BL/5 background were described earlier (Scar-
lett et al., 2012). All animals were maintained in specific pathogen-free barrier
facilities and used in accordance with the institutional animal care and use
guidelines of the Wistar Institute. Ovarian and sarcoma tumor-bearing mice
were euthanized if they showed ruffled fur, lethargy, anorexia, reluctance to
move, ocular discharge, or labored respiration.
T Cell Tumor Antigen Priming
T cells tumor-free Cd4-cre+Foxp1f/f (Foxp1-deficient) or Cd4-creFoxp1f/f
control littermates mice were primed with tumor antigen-pulsed bone-marrow
dendritic cells (BMDCs) as described (Nesbeth et al., 2009) with slight varia-
tions. Briefly, day six BMDCs were pulsed overnight with g-irradiated
(10,000 rad) and UV-treated (30 min) ID8-Defb29-Vegf-a, MPKAS tumor cells
or NIH 3T3 fibroblasts at a 10:1 (DC:tumor cell) ratio. For Trp53-Kras flank tu-
mors, DCs were primed with lysates from advanced dissociated tumors sub-
jected to nine quick freeze and thaw cycles. Tumor antigen-pulsed BMDCs
were cocultured with Foxp1-deficient or WT T cells at a 1:10 (DC to T cell) ratio
in the presence of IL-2 (10 U/ml) and IL-7 (1 ng/ml) (both from Peprotech) for
7 days. Antigen-primed T cells on day 7 were either analyzed immediately
(following Cell Trace Violet labeling in some experiments) or transferred into
congenic autologous tumor-bearing or tumor-free mice.
Tumor Induction and T Cell Immunotherapy
ID8-Defb29-Vegf-a ovarian tumors were induced in CD45.1+ congenic female
mice as reported previously (Cubillos-Ruiz et al., 2009; Nesbeth et al., 2009).
Briefly, 23 106 ID8-Defb29-Vegf-a tumor cells were injected intraperitoneally.
Tumor-bearing mice received 2 3 106 antigen primed T cells intraperitoneally
on day 24 posttumor challenge and were evaluated for disease progression
and survival. ID8-Defb29-Vegf-a flank tumors were induced by subcutaneous
injection of 23 106 tumor cells in the axilla. MPKAS sarcomaswere induced by
injecting 1 3 105 tumor cells subcutaneously in the flank of 6- to 8-week-old
male mice. To induce flank tumors in Trp53-Kras transgenic mice, we subcu-
taneously injected 108 pfu adenovirus-expressing Cre (Gene Transfer Vector
Core, University of Iowa) into the dorsolateral flank. Tumor antigen-primed
T cells were intratumorally injected into palpable tumors three times (once
per week), followed by measuring of tumor growth.ImImmunoprecipitation
All primary human tissues used in this study were procured under IRB regula-
tions. HeLa cells were transfected with HA-tagged human Smad2 (Smad2-HA)
and Flag-tagged human Foxp1 (Foxp1-Flag) with Lipofectamine 2000 (Life
Technologies). After 6 hr of transfection, cells were treated with TGF-b1
(5 ng/ml) or left untreated for 24 hr. CD3 and CD28 activated human CD8+
T cells were electroporated with human Smad2-HA and human Foxp1-Flag
with Amaxa Nucleofector system (Lonza) according to themanufacturer’s pro-
tocols. Six hr later, electroporated cells were treated with TGF-b1 for a total of
24 hr. Mouse CD8+ T cells for Foxp1 immunoprecipitation were in vitro stimu-
lated with CD3 and CD28 microbeads (Invitrogen) in the presence of TGF-b1
for 24 hr. Cells were treated with Dithiobis[succinimidyl propionate] (DSP;
Thermo Scientific) to crosslink proteins, lysed in RIPA buffer supplemented
with a protease inhibitor (Roche), and HA or Smad 2 and 3 were immunopre-
cipitated with Protein A/G agarose (Millipore) using HA.11 (16B12) (Covance)
or Smad2/3 (BD Transduction Laboratories) antibodies followed by immuno-
blotting for Flag (M2) (Sigma Aldrich) or Foxp1. For immunoprecipitating
Flag, transfected HeLa cells were crosslinked, lysed in buffer containing
50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% TRITON X-
100, and immunoprecipitated with Anti-Flag M2 affinity gel (Sigma Aldrich)
as per manufacturer’s instruction. Immunoprecipitated proteins were resolved
with SDS-PAGE and immunobloted for Smad2 and Smad3.
Immunoblotting
Cells were lysed in RIPA buffer (Pierce) supplemented with protease inhibitors
(Roche) and phosphatase inhibitors (Sigma Aldrich) and 0.1 mM Sodium Or-
thovanadate on ice. Proteins were resolved on SDS-PAGE and immunoblot-
ted. Antibodies to Foxp1 (rabbit polyclonal; Feng et al., 2011, a gift from Hui
Hu), b-actin (Sigma Aldrich), TGF-bRII (K105), Smad2 and Smad3 (Smad2/3;
D7G7), phospho-Smad2 (S465/467), phospho-Smad3 (S423/425), c-Jun
(60A8), phospho-cJun (Ser73; D47G9), c-Myc (D84C12), Nfat2 (D15F1) (all
from Cell Signaling Technologies), and Flag-HRP (M2) (Sigma-Aldrich) were
used for immunoblotting.
ChIP
ChIP assays were performed as reported previously (Yashiro-Ohtani et al.,
2009), with rabbit polyclonal antibody to Foxp1. Input DNA and immunoprecip-
itated DNA were analyzed with the SYBR Green in a real-time PCR machine
(Applied Biosystem). The sequences of primers used for promoter quantifica-
tion were: c-Myc, 50-CCTCACTCAGCTCCCCTCCT-30 and 50-CCCTCCC
CTCCCTTCTTTTT-30; c-Jun: 50- AGTTGCACTGAGTGTGGCAGAG-30 and
50-AAGTCCGTCCGTCTGTCTGTCT-30. The primers used for the quantifica-
tion of the MISIIR promoter were 50-CAGCCGTTAGGAGTTGTTAGGTG-30
and 50-ATGGTGTGCAGACATACATGCAG-30 (all sequences designed to
give approximately 80 bp amplicons). Results shown for each ChIP condition
were analyzed in two ways: By using the percent input method, the amount of
DNA recovered from the ChIP were divided by signals obtained from the input
sample (signals calculated with 2.5% of the amount of chromatin used in the
ChIP). By using the fold enrichment method, the ChIP signals were divided
by the irrelevant antibody signals, representing the ChIP signal as the fold in-
crease in signal relative to the background signal.
Statistical Analysis
Mann-WhitneyU tests were used for calculating differences betweenmeans of
experimental groups, and the log rank test was used when analyzing survival
experiments. All statistical analysis was performed with GraphPad Prism 5.0
software. A p value of less than 0.05 was considered statistically significant.
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